The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury

Vince Siebert, Joseph Allencherril, Yumei Ye, Xander H.T. Wehrens, Yochai Birnbaum

Research output: Contribution to journalArticle

Abstract

MicroRNAs (miRNA) are non-coding RNAs that regulate gene expression in up to 90% of the human genome through interactions with messenger RNA (mRNA). The expression of miRNAs varies and changes in diseased and healthy states, including all stages of myocardial ischemia-reperfusion and subsequent ischemia-reperfusion injury (IRI). These changes in expression make miRNAs an attractive potential therapeutic target. Herein, we review the differences in miRNA expression prior to ischemia (including remote ischemic conditioning and ischemic pre-conditioning), the changes during ischemia-reperfusion, and the changes in miRNA expression after IRI, with an emphasis on inflammatory and fibrotic pathways. Additionally, we review the effects of manipulating the levels of certain miRNAs on changes in infarct size, inflammation, remodeling, angiogenesis, and cardiac function after either ischemia-reperfusion or permanent coronary ligation. Levels of target miRNA can be increased using molecular mimics (“agomirs”), or can be decreased by using “antagomirs” which are antisense molecules that act to bind and thus inactivate the target miRNA sequence. Other non-coding RNAs, including long non-coding RNAs and circular RNAs, also regulate gene expression and have a role in the regulation of IRI pathways. We review the mechanisms and downstream effects of the miRNAs that have been studied as therapy in both permanent coronary ligation and ischemia-reperfusion models.

Original languageEnglish (US)
JournalCardiovascular Drugs and Therapy
DOIs
StatePublished - Jan 1 2019

Fingerprint

Myocardial Reperfusion Injury
Untranslated RNA
MicroRNAs
Ischemia
Reperfusion Injury
Reperfusion
Ligation
Long Noncoding RNA
Gene Expression
Ischemic Preconditioning
Myocardial Reperfusion
Human Genome
Myocardial Ischemia
Inflammation
Messenger RNA

Keywords

  • Ischemic heart disease
  • microRNA
  • Reperfusion injury

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury. / Siebert, Vince; Allencherril, Joseph; Ye, Yumei; Wehrens, Xander H.T.; Birnbaum, Yochai.

In: Cardiovascular Drugs and Therapy, 01.01.2019.

Research output: Contribution to journalArticle

Siebert, Vince ; Allencherril, Joseph ; Ye, Yumei ; Wehrens, Xander H.T. ; Birnbaum, Yochai. / The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury. In: Cardiovascular Drugs and Therapy. 2019.
@article{93b1d4de32f044f88bd87789b78de68d,
title = "The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury",
abstract = "MicroRNAs (miRNA) are non-coding RNAs that regulate gene expression in up to 90{\%} of the human genome through interactions with messenger RNA (mRNA). The expression of miRNAs varies and changes in diseased and healthy states, including all stages of myocardial ischemia-reperfusion and subsequent ischemia-reperfusion injury (IRI). These changes in expression make miRNAs an attractive potential therapeutic target. Herein, we review the differences in miRNA expression prior to ischemia (including remote ischemic conditioning and ischemic pre-conditioning), the changes during ischemia-reperfusion, and the changes in miRNA expression after IRI, with an emphasis on inflammatory and fibrotic pathways. Additionally, we review the effects of manipulating the levels of certain miRNAs on changes in infarct size, inflammation, remodeling, angiogenesis, and cardiac function after either ischemia-reperfusion or permanent coronary ligation. Levels of target miRNA can be increased using molecular mimics (“agomirs”), or can be decreased by using “antagomirs” which are antisense molecules that act to bind and thus inactivate the target miRNA sequence. Other non-coding RNAs, including long non-coding RNAs and circular RNAs, also regulate gene expression and have a role in the regulation of IRI pathways. We review the mechanisms and downstream effects of the miRNAs that have been studied as therapy in both permanent coronary ligation and ischemia-reperfusion models.",
keywords = "Ischemic heart disease, microRNA, Reperfusion injury",
author = "Vince Siebert and Joseph Allencherril and Yumei Ye and Wehrens, {Xander H.T.} and Yochai Birnbaum",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10557-019-06893-x",
language = "English (US)",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury

AU - Siebert, Vince

AU - Allencherril, Joseph

AU - Ye, Yumei

AU - Wehrens, Xander H.T.

AU - Birnbaum, Yochai

PY - 2019/1/1

Y1 - 2019/1/1

N2 - MicroRNAs (miRNA) are non-coding RNAs that regulate gene expression in up to 90% of the human genome through interactions with messenger RNA (mRNA). The expression of miRNAs varies and changes in diseased and healthy states, including all stages of myocardial ischemia-reperfusion and subsequent ischemia-reperfusion injury (IRI). These changes in expression make miRNAs an attractive potential therapeutic target. Herein, we review the differences in miRNA expression prior to ischemia (including remote ischemic conditioning and ischemic pre-conditioning), the changes during ischemia-reperfusion, and the changes in miRNA expression after IRI, with an emphasis on inflammatory and fibrotic pathways. Additionally, we review the effects of manipulating the levels of certain miRNAs on changes in infarct size, inflammation, remodeling, angiogenesis, and cardiac function after either ischemia-reperfusion or permanent coronary ligation. Levels of target miRNA can be increased using molecular mimics (“agomirs”), or can be decreased by using “antagomirs” which are antisense molecules that act to bind and thus inactivate the target miRNA sequence. Other non-coding RNAs, including long non-coding RNAs and circular RNAs, also regulate gene expression and have a role in the regulation of IRI pathways. We review the mechanisms and downstream effects of the miRNAs that have been studied as therapy in both permanent coronary ligation and ischemia-reperfusion models.

AB - MicroRNAs (miRNA) are non-coding RNAs that regulate gene expression in up to 90% of the human genome through interactions with messenger RNA (mRNA). The expression of miRNAs varies and changes in diseased and healthy states, including all stages of myocardial ischemia-reperfusion and subsequent ischemia-reperfusion injury (IRI). These changes in expression make miRNAs an attractive potential therapeutic target. Herein, we review the differences in miRNA expression prior to ischemia (including remote ischemic conditioning and ischemic pre-conditioning), the changes during ischemia-reperfusion, and the changes in miRNA expression after IRI, with an emphasis on inflammatory and fibrotic pathways. Additionally, we review the effects of manipulating the levels of certain miRNAs on changes in infarct size, inflammation, remodeling, angiogenesis, and cardiac function after either ischemia-reperfusion or permanent coronary ligation. Levels of target miRNA can be increased using molecular mimics (“agomirs”), or can be decreased by using “antagomirs” which are antisense molecules that act to bind and thus inactivate the target miRNA sequence. Other non-coding RNAs, including long non-coding RNAs and circular RNAs, also regulate gene expression and have a role in the regulation of IRI pathways. We review the mechanisms and downstream effects of the miRNAs that have been studied as therapy in both permanent coronary ligation and ischemia-reperfusion models.

KW - Ischemic heart disease

KW - microRNA

KW - Reperfusion injury

UR - http://www.scopus.com/inward/record.url?scp=85069526124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069526124&partnerID=8YFLogxK

U2 - 10.1007/s10557-019-06893-x

DO - 10.1007/s10557-019-06893-x

M3 - Article

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

ER -